By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Catabasis Pharmaceuticals, Inc. 

161 First Street
Suite 1A
Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-349-1971 Fax: 617-273-2637


SEARCH JOBS


Industry
Pharmaceutical






Company News
Catabasis (CATB) Provides Edasalonexent And Rare Disease Pipeline Updates At Investor Day 11/17/2016 8:05:09 AM
Catabasis (CATB) Reports Third Quarter 2016 Financial Results And Recent Corporate Highlights 11/11/2016 12:54:40 PM
Catabasis (CATB) Presents Positive Data For CAT-5571, A Novel Activator Of Autophagy, As A Potential Oral Treatment For Cystic Fibrosis At The 30th Annual North American Cystic Fibrosis Conference 10/27/2016 10:44:15 AM
Catabasis (CATB) To Report Third Quarter 2016 Financial Results And Recent Corporate Developments On Thursday, November 10 10/26/2016 10:20:31 AM
Catabasis (CATB) To Present The MoveDMD Trial Of Edasalonexent (CAT-1004), A Potential Disease-Modifying Therapy For DMD, At The American Neurological Association’s 2016 Annual Meeting 10/11/2016 11:47:08 AM
Catabasis (CATB) Presents Positive Data From Part A Of The MoveDMD Trial Of Edasalonexent (CAT-1004), A Potential Disease-Modifying Therapy For DMD, At The World Muscle Society Congress 10/6/2016 10:16:36 AM
Catabasis (CATB) Presents Positive Data From Part A Of The MoveDMD Trial Of Edasalonexent (CAT-1004), A Potential Disease-Modifying Therapy For DMD, At The World Muscle Society Congress 10/6/2016 7:40:48 AM
Catabasis (CATB) Announces Promotion Of Andrew Nichols, Ph.D. To Chief Scientific Officer And Angelika Fretzen To Senior Vice President Of Product Development 10/5/2016 11:08:29 AM
Catabasis (CATB) Completes Target Enrollment For Part B Of The MoveDMD Trial, A Phase II Trial Of Edasalonexent (CAT-1004) For The Potential Treatment Of Duchenne Muscular Dystrophy 10/4/2016 11:31:59 AM
Catabasis (CATB) Announces Closing Of $11.5 Million Offering Of Common Stock, Including Full Exercise Of Underwriter’s Option To Purchase Additional Shares 9/29/2016 10:35:42 AM
12345678910...
//-->